Anyone knows what happened to RTL 1000? They completed the Phase 1 of the clinical trials more than 2 years ago, back in the fall of 2009 and since then there is no Phase 2 initiated. Would it take years to start Phase 2 after successfully completing Phase 1? 2 years ago Al Ferro, President and CEO of Artielle ImmunoTherapeutics, Inc. said that "We plan to move aggressively to bring these novel, first-in-class products to the market place."
The compound seemed really interesting as previous studies implied that RTL1000 demonstrate repair of the myelin sheath and it might cause less damage than do current drugs on the market.